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Introduction
Lung cancer is the leading cause of tumor-specific death in many countries nowadays, and its incidence rate is rising every year. 1 The main pathological type of lung cancer, which covers >80%, is non-small cell lung cancer (NSCLC). It appears that lymph node metastasis of lung cancer may occur early, and latter lung cancer can metastasize to other distant organs. Metastatic spread constitutes the primary source of morbidity and mortality, and influences the effect of the patients' treatment and prognosis. 2 Although the regional development of NSCLC is not as aggressive as small-cell lung cancer, micrometastasis may occur in NSCLC and it will seriously influence the patients' prognosis. Accumulating evidence suggests that constitutively activated signal transducer and activator of transcription 3 (STAT3) has been found to be related to tumor development and progression in numerous forms of primary cancers. Persistent phosphorylation of STAT3 has been shown in 22~65% of NSCLC. The constantly activated STAT3 contributes to oncogenesis by upregulation of genes encoding bcl-xl, bcl-2, cyclinD1, c-myc, survivin, mcl-1, vascular endothelial growth factor, interleukin-10, and so on, which can protect apoptosis, enhance cell proliferation, promote angiogenesis, and evade immune surveillance. 3, 4 There are several methods to test tumor micrometastasis, such as polymerase chain reaction (PCR), immunohistochemistry, flow cytometry, western blot, and so on. 5 PCR is considered to be an ideal method, and mucin 1 (MUC1) mRNA is a selective target gene for tumor micrometastasis detection using PCR.
Therefore, we wanted to explore whether STAT3 can be related to lymph node micrometastasis of NSCLC. To address this question, we evaluated the expression of MUC1 mRNA in the lymph node samples of NSCLC to determine micrometastasis. Then, we evaluated what role STAT3 overexpression plays in lymph node micrometastasis of NSCLC. 
Western blot
The tissues were lysed in lysing buffer and total protein was estimated by using the bichloroacetic acid method. The whole cell extracts (20 μg/lane) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to nitrocellulose membrane. After blocked in Tris-buffered saline with 5% (w/v) non-fat dry milk, membranes were incubated with primary antibodies (1:100 dilution) according to the manufacturer's instructions, and then incubated with horseradish peroxidase conjugated secondary antibody. The protein bands were recorded on X-ray film and examined.
Immunohistochemistry
Immunohistochemical staining for STAT3 and phosphorylated STAT3 (pSTAT3) protein was performed using the 
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Thoracic Cancer 9 (2018) 516-522streptavidin-peroxidase method. Slides were deparaffinized and rehydrated with xylene and graded alcohol. Optimal antigen retrieval was carried out in citrate buffer (pH = 6.0) for 10 min with a steam oven to enhance the immunoreactivity. The protein expression was scored semiquantitatively by the proportion of the stained tumor nuclei or cytoplasm as follows: staining proportion was classified as 0 to 3 (0 = 0~5% positive cells, 1 = 5~25% positive cells, 2 = 25~50%, 3 ≥50%). Two independent observers did the semiquantitative scoring of the expression levels of STAT3 and pSTAT3 proteins, and both observers re-examined the immunostained slides to determine a consensus score.
Statistical analysis
All statistical analyses were performed with SPSS 11.5 statistical software (SPSS Inc., Chicago, IL, USA). Measurement data were represented as mean AE standard deviation, and the t-rest or F-test were used. The χ 2 -test was used in enumeration data. Logistic regression analysis was performed to determine the independent risk factors influencing lymph node micrometastasis of early-stage NSCLC. Differences were considered significant when the P-value was <0.05.
Results

Results of reverse transcription PCR
We examined MUC1 mRNA expression by reverse transcription PCR in all samples of lymph nodes, and STAT3 mRNA expression in all NSCLC and normal lung tissue samples (Figs 1-2 ). MUC1 mRNA expression was detected in 33 lymph node samples that belong to 19 NSCLC patients and 0 in the lymph node samples from patients with benign lung tumors ( Table 2 ). STAT3 mRNA expression values in NSCLC and normal lung tissue samples were 0.8019 AE 0.1462 and 0.3303 AE 0.0236, respectively (t 0 = 22.105, P = 0.000). In NSCLC with lymph node micrometastasis, the STAT3 mRNA expression value was 0.9502 AE 0.1004 and that of NSCLC without lymph node micrometastasis was 0.7110 AE 0.0800. STAT3 mRNA overexpression in NSCLC samples correlated with lymph node micrometastasis status (t = 9.308, P = 0.000), tumor differentiation degree (t = −6.936, P = 0.000) and the pathological TNM stage (F = 36.001, P = 0.000), but not correlated with age, gender, and histological type ( Table 3) .
Results of western blot
The expression value of STAT3 protein and pSTAT3 protein in NSCLC samples were 0.9459 AE 0.1375 and 0.6503 AE 0.1510, which were much higher than that expressed in normal lung tissue samples (0.3887 AE 0.0269 and 0.2192 AE 0.0215). The expression value of STAT3 protein and pSTAT3 protein in NSCLC samples with lymph node micrometastasis were 1.0860 AE 0.0783 and 0.7987 AE 0.0936, which were also higher than that expressed in lung cancer samples without lymph node micrometastasis (0.8600 AE 0.0846 and 0.5593 AE 0.0972). The result is shown in Figure 3 . Through statistical analysis, STAT3 and pSTAT3 overexpression in NSCLC samples correlated with lymph node micrometastasis status (t = 9.427, P = 0.000; t = 8.572, P = 0.000), tumor differentiation degree (t = −6.876, P = 0.000; t = −8.003, P = 0.000), and the TNM stage (F = 32.589, P = 0.000; F = 29.031, P = 0.000), but had no significant correlation with age, gender, and histological type ( Table 4) .
Results of immunohistochemistry
The expression rate of STAT3 protein and pSTAT3 protein in lung cancer samples with lymph node micrometastasis were 94.74% and 73.68% using the immunohistochemistry method, which were also higher than that in lung cancer samples without lymph node micrometastasis (both were 38.71%). No STAT3 protein and pSTAT3 protein were detected in normal lung tissue samples (Fig 4) . STAT3 and pSTAT3 overexpression in NSCLC samples correlated with lymph node micrometastasis (χ 2 = 15.407, P = 0.000; χ 2 = 5.773, P = 0.016), tumor differentiation degree (χ 2 = 11.092, P = 0.001; χ 2 = 12.738, P = 0.000), and the TNM stage (χ 2 = 8.750, P = 0.013; χ 2 = 12.139, P = 0.002), but had no significant correlation with age, gender, and histological type (Table 5) .
Logistic regression analysis
Logistic regression analysis was carried out to determine the independent risk factors influencing lymph node micrometastasis of early-stage NSCLC. The result revealed that STAT3 protein overexpression in tumors (OR 13.379, P = 0.033) and the differentiation degree of tumors (OR 0.131, P = 0.016) were independent risk factors for (Table 6 ).
Discussion
The involvement of lymph node metastasis is a very important prognostic factor in patients with potentially resectable NSCLC, and postoperative early recurrence often occurred in early-stage NSCLC patients with lymph node micrometastasis. Accurate staging of individual patients remains a critical need. It guides the choice of therapy and stratifies patients appropriately for clinical trial of novel interventions. It also facilitates the comparison of treatment outcomes. Although patients with early-stage NSCLC
show an excellent prognosis, a few of them die of metastatic disease. In this subgroup of individuals, the search of occult metastasis might reveal that early dissemination of tumor cells could be the cause of cancer progression. Disseminated tumor cells are regarded as a surrogate for early metastatic spread of disease. These cells can be detected in peripheral blood, bone marrow aspirates, and lymph nodes, where we refer to them as circulating tumor cells. Detection of disseminated tumor cells is a great technical challenge, and many different technologies have been developed to enhance the sensitivity and specificity of the testing for it. Different characteristics of tumor cells have been used to establish enrichment methods, including the differential expression of tumor-specific markers on the surface of the cells, the size-based selection of the cells, and other physical properties. The detection of circulating tumor cells has emerged in recent years as a biomarker with outstanding predictive and prognostic capacity in a number of malignancies including breast, prostate, lung, and colorectal cancer. However, the mechanism of micrometastasis is still unclear. STAT3 has been reported to be correlated with lymph node metastasis of many human malignancies. 3 Researchers reported that STAT3 expression was an independent risk factor for the prognosis of colorectal and gastric carcinoma 6, 7 Abdulghani et al. reported that STAT3 promotes metastatic progression of prostate cancer 8 Sato et al. reported that STAT3 promotes lymph node metastasis and correlates with breast cancer prognosis. 9 So, what about the relationship between STAT3 expression and lymph node micrometastasis of early-stage NSCLC? In order to test this hypothesis, we designed the present study, and we want to highlight some of the possibilities associated with developing a way to detect tumor micrometastasis and an anticancer drug that might therapeutically inhibit the STAT3 signaling pathway.
In this study, we found the STAT3 mRNA expression value, STAT3 protein and pSTAT3 protein expression values of lung cancer with lymph node micrometastasis were all much higher than that expressed in lung cancer samples without lymph node micrometastasis (P < 0.05). The expression rate of STAT3 protein and pSTAT3 protein in lung cancer samples with lymph node micrometastasis were also higher than that in lung cancer samples without lymph node micrometastasis (P < 0.05). Logistic regression analysis revealed that STAT3 protein overexpression in tumors and the differentiation degree of tumors were independent risk factors for lymph node micrometastasis of early-stage NSCLC.
Metastasis is a complex process that consists of a few detailed steps including dissemination of tumor cells from primary sites, transportation of tumor cells within the lymphatics, settlement of tumor cells within lymph nodes, and re-growth of tumors into a detectable size. The contribution of STAT3 to cancer has been widely confirmed by numerous studies demonstrating dysregulated activation in a variety of human tumors. Although the real mechanism of STAT3 on tumor metastasis is still unclear, it has been reported to promote tumor proliferation, survival, prevention of apoptosis and angiogenesis by upregulating the expression of its downstream genes such as survivin, bcl-xl, cyclinD1, c-myc, vascular endothelial growth factor, and so on. STAT3 can be activated through several ways, such as the JAK-STAT pathway and Ras-mitogen-activated protein kinase pathway, and it can also be activated by many extracellular signals, such as interleukin-6, interleukin-11, leukemia inhibitory factor, epidermal growth factor, fibroblast growth factor, thyroid-stimulating hormone, and so on. 10 In this study, logistic regression analysis revealed that STAT3 protein overexpression in tumors and the differentiation degree of tumors were independent risk factors for lymph node micrometastasis of early-stage NSCLC. It is anticipated that new anticancer strategies will be developed to inhibit lymph node metastasis and improve the patients' prognosis.
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